Almirall SA
MAD:ALM
Almirall SA
Operating Income
Almirall SA
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Almirall SA
MAD:ALM
|
Operating Income
€49.6m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-21%
|
|
|
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
|
Operating Income
€179.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
33%
|
CAGR 10-Years
21%
|
|
|
F
|
Faes Farma SA
MAD:FAE
|
Operating Income
€108.5m
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
13%
|
|
|
Laboratorio Reig Jofre SA
MAD:RJF
|
Operating Income
€15m
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
11%
|
|
|
L
|
Labiana Health SA
MAD:LAB
|
Operating Income
-€1.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Almirall SA
Glance View
Almirall SA, a venerable player in the pharmaceutical industry, has its roots deeply embedded in the Spanish landscape where it began its journey in 1943. With a commitment to innovation and a keen focus on dermatology, the company has carved out a significant niche for itself. Almirall's core strategy revolves around the development, manufacturing, and commercialization of its proprietary medications, particularly those targeting skin conditions such as psoriasis and atopic dermatitis. By investing heavily in research and development, Almirall ensures its pipeline remains robust with promising drug candidates and innovative therapies that can meet the unmet needs of dermatology patients. This focus gives them a strategic edge, allowing them to leverage their scientific expertise and deliver state-of-the-art solutions to the market. The financial health of Almirall thrives on a clear business model that involves both direct sales and strategic partnerships. Through collaborations with other pharmaceutical giants and dynamic distribution networks, the company expands its reach beyond Europe, tapping into the American and Asian markets as well. Licensing agreements and co-development partnerships are key to its financial strategy, effectively allowing Almirall to maximize its intellectual property while sharing risks and costs. This multi-pronged approach ensures a steady revenue stream from both its branded products and its generics division, which supplements the overall profitability and sustainability of the company. As Almirall continues to navigate the competitive landscape of the pharma industry, its resilience and adaptability underscore its enduring legacy.
See Also
What is Almirall SA's Operating Income?
Operating Income
49.6m
EUR
Based on the financial report for Dec 31, 2024, Almirall SA's Operating Income amounts to 49.6m EUR.
What is Almirall SA's Operating Income growth rate?
Operating Income CAGR 10Y
-21%
Over the last year, the Operating Income growth was 23%. The average annual Operating Income growth rates for Almirall SA have been -21% over the past three years , -14% over the past five years , and -21% over the past ten years .
You don't have any saved screeners yet